Table 1 Characteristics of the included studies.
Study | Year | Country | Ethnicity | Sample size | PCa type | Treatment method | Cut-off value Of NLR | Survival analysis |
|---|---|---|---|---|---|---|---|---|
Shafique16 | 2012 | UK | Caucasian | 709 | All PCa | NR | 5 | OS |
Linton15 | 2013 | Australia | Caucasian | 182 | mCRPC | Chemotherapy | 5 | OS |
Nuhn12 | 2014 | USA | Caucasian | 247 | mCRPC | Chemotherapy | 3 | OS |
Sumbul25 | 2014 | Turkey | Asian | 33 | mCRPC | Chemotherapy | 3 | PFS |
Templeton13 | 2014 | Canada | Caucasian | 357 | mCRPC | Chemotherapy | 3 | OS |
Bahig24 | 2015 | Canada | Caucasian | 950 | Localized PCa | Radiotherapy | 3 | OS,PFS |
Kwon23 | 2015 | USA | Caucasian | 217 | Localized PCa | Prostatectomy | 2.6 | RFS |
Langsenlehner14 | 2015 | Austria | Caucasian | 415 | Localized PCa | Radiotherapy | 5 | OS,PFS |
Lee22 | 2015 | Korea | Asian | 1367 | Localized PCa | Prostatectomy | 2.5 | RFS |
Lorente21 | 2015 | UK | Caucasian | 755 | mCRPC | Chemotherapy | 3 | OS,PFS |
Poyet20 | 2015 | Switzerland | Caucasian | 399 | Localized PCa | Prostatectomy | 2.67 | RFS |
Sharma19 | 2015 | USA | Caucasian | 8350 | Localized PCa | Prostatectomy | 5 | OS,PFS |
Soest117 | 2015 | Netherland | Caucasian | 1224 | mCRPC | Chemotherapy | 2 | OS |
Soest217 | 2015 | Netherland | Caucasian | 1006 | mCRPC | Chemotherapy | 2.1 | OS |
Yao18 | 2015 | Japan | Asian | 55 | mCRPC | Chemotherapy | 3.5 | OS,PFS |
